Drug lookup
Drug reference

beclomethasone dipropionate

Inhaled corticosteroid · Anti-asthmatic, Anti-inflammatory (pulmonary), Corticosteroid (inhaled), Anti-allergic rhinitis (nasal spray for ciclesonide prodrug usage noted, applicable here too for general ICS class info about nasal sprays later in the book likely not this chapter, but contextually for BDP, it's focused on pulmonary). I will stick to pulmonary categories directly supported by the text for BDP. The text explicitly mentions ciclesonide nasal spray. For BDP, it's

Inhaled corticosteroidAnti-asthmatic, Anti-inflammatory (pulmonary), Corticosteroid (inhaled), Anti-allergic rhinitis (nasal spray for ciclesonide prodrug usage noted, applicable here too for general ICS class info about nasal sprays later in the book likely not this chapter, but contextually for BDP, it's focused on pulmonary). I will stick to pulmonary categories directly supported by the text for BDP. The text explicitly mentions ciclesonide nasal spray. For BDP, it's
CDSCO approved
EXCRETION
not curated
INTERACTIONS
none in our sources
PREGNANCY
A
FDA category + note

Mechanism

Not yet extracted

Indications

Persistent asthma (when inhaled β2 agonists are required almost daily or the disease is not only episodic)Prophylaxis of asthmaPerennial rhinitis (intranasal spray)Variety of dermatological conditionsSevere inflammatory conditionsUnresponsive eczemaPsoriasis

Dosing

Adult
100–200 µg BD, titrate dose upward every 3–5 days; max 400 µg QID by inhalation (for asthma). 50 µg in each nostril BD–TDS (intranasal spray for perennial rhinitis).

Pharmacokinetics

Bioavailability
Low systemic activity due to poor absorption and/or marked first-pass metabolism

Contraindications

  • No role during an acute attack or in status asthmaticus

Side effects

Common
Hoarseness of voiceDysphoniaSore throatAsymptomatic or symptomatic oropharyngeal candidiasisThinning of epidermisDermal atrophyTelangiectasiaStriaeEasy bruisingHypopigmentationDelayed wound healingFungal and bacterial infections
Serious
  • Mood changes (at doses > 600 µg/day)
  • Osteoporosis (at doses > 600 µg/day)
  • Growth retardation in children (at doses > 600 µg/day)
  • Bruising (at doses > 600 µg/day)
  • Petechiae (at doses > 600 µg/day)
  • Hyperglycaemia (at doses > 600 µg/day)
  • Pituitary-adrenal suppression (at doses > 600 µg/day)
  • Adrenal crisis
  • Adrenal pituitary suppression (with large, repeated amounts)
  • Cushing’s syndrome (rarely)

Pregnancy & lactation

Pregnancy

A

Related guidelines

Ask House about beclomethasone dipropionate

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team